ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups

BACKGROUND: The ATLAS trial, investigating adjuvant axitinib versus placebo in renal cell carcinoma (RCC), was stopped for futility at a preplanned interim analysis. We report subgroup outcome analyses by ethnicity, time on treatment, dose modification and toxicity. PATIENTS AND METHODS: Patient dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Quinn, D.I., Ng, C.F., Grande, E., Kwon, T.G., Linke, R., Lee, J.-L., Rosbrook, B., Thakur, M.N., Eto, M., Gross-Goupil, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099745/
https://www.ncbi.nlm.nih.gov/pubmed/33901868
http://dx.doi.org/10.1016/j.esmoop.2021.100105

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8099745/
https://www.ncbi.nlm.nih.gov/pubmed/33901868
http://dx.doi.org/10.1016/j.esmoop.2021.100105

Ejemplares similares